Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer

Published:2012-06-12 Issue:4 Volume:18 Page:704-710
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Hatano Koji,Nishimura Kazuo,Nakai Yasutomo,Yoshida Takahiro,Sato Mototaka,Kawashima Atsunari,Mukai Masatoshi,Nagahara Akira,Uemura Motohide,Oka Daizo,Nakayama Masashi,Takayama Hitoshi,Shimizu Kiyonori,Meguro Norio,Tanigawa Tsuyoshi,Yamaguchi Seiji,Tsujimura Akira,Nonomura Norio

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-012-0429-1.pdf

Reference30 articles.

1. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

2. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

3. Shimazui T, Kawai K, Miyanaga N et al (2007) Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 37:603–608

4. Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38:365–372

5. Ide H, Kikuchi E, Kono H et al (2010) Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 40:79–84

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management;Scientific Reports;2024-06-11

2. Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer;Anticancer Research;2020-07-29

3. Antitumor Research on Artemisinin and Its Bioactive Derivatives;Natural Products and Bioprospecting;2018-04-09

4. Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels;EUR REV MED PHARMACO;2018

5. Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer;Chemotherapy;2015-11-04